Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2026-02-23 @ 1:10 AM
Study NCT ID:
NCT01869803
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2018-03-02
First Post:
2013-05-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Sponsor:
Wake Forest University Health Sciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | View |
| None | Adult Acute Myeloid Leukemia With Del(5q) | View |
| None | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | View |
| None | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | View |
| None | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | View |
| None | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | View |
| None | Adult Acute Promyelocytic Leukemia (M3) | View |
| None | Childhood Acute Promyelocytic Leukemia (M3) | View |
| None | Recurrent Adult Acute Myeloid Leukemia | View |
| None | Recurrent Childhood Acute Myeloid Leukemia | View |
Keywords: